MIST Trial Reveals Mixed Results For PFO Treatment Of Migraine
This article was originally published in The Gray Sheet
Executive Summary
Preliminary clinical trial data show NMT Medical's STARflex patent foramen ovale (PFO) closure device to be no more effective than placebo in completely eliminating migraine headaches, although the device did appear to improve some symptoms
You may also be interested in...
Enrollment Headaches Cause NMT To Drop Migraine Trial
NMT Medical is halting its chase of a migraine indication for its patent foramen ovale closure device after an earlier trial missed its primary endpoint and a second, larger trial has suffered enrollment problems
Enrollment Headaches Cause NMT To Drop Migraine Trial
NMT Medical is halting its chase of a migraine indication for its patent foramen ovale closure device after an earlier trial missed its primary endpoint and a second, larger trial has suffered enrollment problems
Next Generation Of PFO Closure Systems Aim For Less Device Exposure
Firms are looking ahead to next-generation patent foramen ovale closure devices that leave less of a "footprint" than the standard implant